LG Life Sciences will target $500 million with its first domestic diabetes treatment ‘Zemiglo’
LG Life Sciences will speed up on expanding its first domestic diabetes treatment ‘Zemiglo (generic name: gemigliptin)’ to global markets.
According to the company, Zemiglo, launched on January 2013 after getting an approval in 2012, has grew more than twice up starting from KRW 6 billion at the...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
